Elias Jabbour graduated from the Saint Joseph’s School of Medicine in 1998 and joined, thereafter, the Hotel Dieu de France University Hospital as a resident. In 2001, he pursued a fellowship in hematology-oncology at the Gustave Roussy Institute. In 2003, he joined the University of Texas M. D. Anderson Cancer as a Fellow at the Department of Hematology/Leukemia and Stem Cell Transplantation. Thereafter, in 2007, he joined the faculty at the Leukemia Department as an Assistant Professor. Dr. Jabbour is actively involved in research in both acute and chronic forms of leukemia. He was actively involved in clinical trials that lead to the approval of several drugs in chronic myeloid leukemia (CML) and myelodysplastic syndromes. His researches on resistance to imatinib and mutations of the protein kinase domain were presented in several international meetings and published in peer-reviewed journals. He is also developing tailored therapies to CML. Dr. Jabbour has taken an active role in the medical community, participating in numerous scientific meetings. He has authored or coauthored more than 100 medical publications and abstracts and serves as a reviewer for numerous scientific journals. In 2005, 2006, and 2007, he received the American Society of Clinical Oncology and the American Society of Hematology merit awards for Outstanding Clinical Fellow, in addition to two similar awards from the American Society of Bone Marrow Transplantation.
Biography Updated on 27 September 2009